Massachusetts Financial Services
NRIX icon

Massachusetts Financial Services’s Nurix Therapeutics NRIX Stock Holding History

Massachusetts Financial Services’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-42,603
Closed -$660K – 1044
2026
Q1 		$660K Sell
42,603
-1,140
-3% -$18.9K ﹤0.01% 876
2025
Q4 		$830K Sell
43,743
-2,866
-6% -$41.2K ﹤0.01% 838
2025
Q3 		$431K Buy
46,609
+3,065
+7% +$31.8K ﹤0.01% 836
2025
Q2 		$496K Buy
43,544
+538
+1% +$5.81K ﹤0.01% 849
2025
Q1 		$511K Sell
43,006
-24,398
-36% -$408K ﹤0.01% 847
2024
Q4 		$1.27M Sell
67,404
-2,011
-3% -$46.1K ﹤0.01% 798
2024
Q3 		$1.56M Sell
69,415
-28,756
-29% -$651K ﹤0.01% 757
2024
Q2 		$2.05M Sell
98,171
-14,608
-13% -$227K ﹤0.01% 745
2024
Q1 		$1.66M Sell
112,779
-29,367
-21% -$316K ﹤0.01% 747
2023
Q4 		$1.47M Buy
142,146
+101,320
+248% +$694K ﹤0.01% 745
2023
Q3 		$321K Buy
40,826
+20,020
+96% +$183K ﹤0.01% 823
2023
Q2 		$208K Sell
20,806
-490
-2% -$5K ﹤0.01% 812
2023
Q1 		$189K Buy
+21,296
New +$222K ﹤0.01% 835

Other funds holding NRIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Massachusetts Financial Services's NRIX Position: Q2 2026 in Review

Massachusetts Financial Services sold out of Nurix Therapeutics (NRIX) in Q2 2026, closing a stake of 42,603 shares — an estimated $660K sold.

Massachusetts Financial Services first reported a position in NRIX in Q1 2023 and held it in 13 quarters. The position peaked at $2.05M in Q2 2024. 212 funds tracked by Wall St. Rank hold NRIX as of Q2 2026.

  • Massachusetts Financial Services reported no remaining Nurix Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Massachusetts Financial Services sold 42,603 Nurix Therapeutics shares in Q2 2026, an estimated $660K.
  • Massachusetts Financial Services first reported a position in Nurix Therapeutics in Q1 2023 and held it in 13 quarters.
  • Massachusetts Financial Services's Nurix Therapeutics position peaked at $2.05M in Q2 2024.
  • 212 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2026.

Based on Massachusetts Financial Services's 13F filing for Q2 2026, filed 3 Aug 2026.